Common Contracts
4 similar Registration Rights Agreement contracts by Inspire Pharmaceuticals Inc, Neurogen Corp, Warburg Pincus Private Equity IX, L.P., Warburg Pincus Private Equity Viii L P
NEUROGEN CORPORATION REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • April 14th, 2008 • Warburg Pincus Private Equity Viii L P • Pharmaceutical preparations • New York
This REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is made as of April 7, 2008, by and among Neurogen Corporation, a Delaware corporation (the “Company”) and each person listed on Exhibit A attached hereto (collectively, the “Investors” and each individually, an “Investor”). Capitalized terms used herein and not otherwise defined shall have the meanings ascribed to them in Section 9(q) herein.
NEUROGEN CORPORATION REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • April 11th, 2008 • Neurogen Corp • Pharmaceutical preparations • New York
This REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is made as of April 7, 2008, by and among Neurogen Corporation, a Delaware corporation (the “Company”) and each person listed on Exhibit A attached hereto (collectively, the “Investors” and each individually, an “Investor”). Capitalized terms used herein and not otherwise defined shall have the meanings ascribed to them in Section 9(q) herein.
INSPIRE PHARMACEUTICALS, INC. Series A Exchangeable Preferred Stock REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • July 23rd, 2007 • Warburg Pincus Private Equity IX, L.P. • Pharmaceutical preparations • New York
This Registration Rights Agreement (this “Agreement”), dated July 20, 2007, among Inspire Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and the investors from time to time signatory hereto (each such investor, an “Investor” and all such investors collectively, the “Investors”), is entered into pursuant to that certain Securities Purchase Agreement, dated July 17, 2007, among the Company and Warburg Pincus Private Equity IX, L.P. (the “Purchase Agreement”), providing for the Company’s issuance and sale of an aggregate of 140,186 shares (the “Exchangeable Preferred Stock”) of Series A Preferred Stock, in the amounts set forth on Exhibit A to the Purchase Agreement. The Series A Preferred Stock will be exchangeable into shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), as set forth in the applicable Certificate of Designations. Capitalized terms used herein and not otherwise defined shall have the meanings ascribed to them in Section 9
INSPIRE PHARMACEUTICALS, INC. Series A Exchangeable Preferred Stock REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • July 23rd, 2007 • Inspire Pharmaceuticals Inc • Pharmaceutical preparations • New York
This Registration Rights Agreement (this “Agreement”), dated July 20, 2007, among Inspire Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and the investors from time to time signatory hereto (each such investor, an “Investor” and all such investors collectively, the “Investors”), is entered into pursuant to that certain Securities Purchase Agreement, dated July 17, 2007, among the Company and Warburg Pincus Private Equity IX, L.P. (the “Purchase Agreement”), providing for the Company’s issuance and sale of an aggregate of 140,186 shares (the “Exchangeable Preferred Stock”) of Series A Preferred Stock, in the amounts set forth on Exhibit A to the Purchase Agreement. The Series A Preferred Stock will be exchangeable into shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), as set forth in the applicable Certificate of Designations. Capitalized terms used herein and not otherwise defined shall have the meanings ascribed to them in Section 9
